BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32634582)

  • 1. N-Acylethanolamine Acid Amidase contributes to disease progression in a mouse model of multiple sclerosis.
    Pontis S; Palese F; Summa M; Realini N; Lanfranco M; De Mei C; Piomelli D
    Pharmacol Res; 2020 Oct; 160():105064. PubMed ID: 32634582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-Acylethanolamine-Hydrolyzing Acid Amidase Inhibition, but Not Fatty Acid Amide Hydrolase Inhibition, Prevents the Development of Experimental Autoimmune Encephalomyelitis in Mice.
    Bottemanne P; Guillemot-Legris O; Paquot A; Masquelier J; Malamas M; Makriyannis A; Alhouayek M; Muccioli GG
    Neurotherapeutics; 2021 Jul; 18(3):1815-1833. PubMed ID: 34235639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of N-acylethanolamine-hydrolyzing acid amidase reduces T cell infiltration in a mouse model of multiple sclerosis.
    Sgroi S; Romeo E; Fruscia PD; Porceddu PF; Russo D; Realini N; Albanesi E; Bandiera T; Bertozzi F; Reggiani A
    Pharmacol Res; 2021 Oct; 172():105816. PubMed ID: 34391933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Inflammatory Effects of Fucoxanthinol in LPS-Induced RAW264.7 Cells through the NAAA-PEA Pathway.
    Jin W; Yang L; Yi Z; Fang H; Chen W; Hong Z; Zhang Y; Zhang G; Li L
    Mar Drugs; 2020 Apr; 18(4):. PubMed ID: 32326173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined in vivo effect of N-acylethanolamine-hydrolyzing acid amidase and glycogen synthase kinase-3β inhibition to treat multiple sclerosis.
    Sgroi S; Romeo E; Albanesi E; Piccardi F; Catalano F; Debellis D; Bertozzi F; Reggiani A
    Biomed Pharmacother; 2024 Jun; 175():116677. PubMed ID: 38701570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue Transglutaminase contributes to experimental multiple sclerosis pathogenesis and clinical outcome by promoting macrophage migration.
    van Strien ME; de Vries HE; Chrobok NL; Bol JGJM; Breve JJP; van der Pol SMP; Kooij G; van Buul JD; Karpuj M; Steinman L; Wilhelmus MM; Sestito C; Drukarch B; Van Dam AM
    Brain Behav Immun; 2015 Nov; 50():141-154. PubMed ID: 26133787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of cyanamides as potent and selective N-acylethanolamine acid amidase inhibitors.
    Malamas MS; Farah SI; Lamani M; Pelekoudas DN; Perry NT; Rajarshi G; Miyabe CY; Chandrashekhar H; West J; Pavlopoulos S; Makriyannis A
    Bioorg Med Chem; 2020 Jan; 28(1):115195. PubMed ID: 31761726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation-restricted anti-inflammatory activities of a N-acylethanolamine acid amidase (NAAA) inhibitor F215.
    Li Y; Zhou P; Chen H; Chen Q; Kuang X; Lu C; Ren J; Qiu Y
    Pharmacol Res; 2018 Jun; 132():7-14. PubMed ID: 29572189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The nod-like receptor, Nlrp12, plays an anti-inflammatory role in experimental autoimmune encephalomyelitis.
    Gharagozloo M; Mahvelati TM; Imbeault E; Gris P; Zerif E; Bobbala D; Ilangumaran S; Amrani A; Gris D
    J Neuroinflammation; 2015 Oct; 12():198. PubMed ID: 26521018
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Piomelli D; Scalvini L; Fotio Y; Lodola A; Spadoni G; Tarzia G; Mor M
    J Med Chem; 2020 Jul; 63(14):7475-7490. PubMed ID: 32191459
    [No Abstract]   [Full Text] [Related]  

  • 11. Interleukin-33 deficiency exacerbated experimental autoimmune encephalomyelitis with an influence on immune cells and glia cells.
    Xiao Y; Lai L; Chen H; Shi J; Zeng F; Li J; Feng H; Mao J; Zhang F; Wu N; Xu Y; Tan Z; Gong F; Zheng F
    Mol Immunol; 2018 Sep; 101():550-563. PubMed ID: 30173119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NAAA inhibitor F96 attenuates BBB disruption and secondary injury after traumatic brain injury (TBI).
    Li Y; Zhou P; Hu T; Ren J; Xu Y; Qiu Y; Lu C; Li Y
    Eur J Pharmacol; 2021 Dec; 912():174561. PubMed ID: 34655598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-Acylethanolamine acid amidase (NAAA) inhibitor F215 as a novel therapeutic agent for osteoarthritis.
    Zhou P; Xiang L; Yang Y; Wu Y; Hu T; Liu X; Lin F; Xiu Y; Wu K; Lu C; Ren J; Qiu Y; Li Y
    Pharmacol Res; 2019 Jul; 145():104264. PubMed ID: 31063807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ramulus Cinnamomi essential oil exerts an anti-inflammatory effect on RAW264.7 cells through N-acylethanolamine acid amidase inhibition.
    Jia W; He X; Jin W; Gu J; Yu S; He J; Yi Z; Cai B; Gao H; Yang L
    J Ethnopharmacol; 2023 Dec; 317():116747. PubMed ID: 37311500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of potent N-acylethanolamine-hydrolyzing acid amidase (NAAA) inhibitor as anti-inflammatory compounds.
    Li Y; Yang L; Chen L; Zhu C; Huang R; Zheng X; Qiu Y; Fu J
    PLoS One; 2012; 7(8):e43023. PubMed ID: 22916199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of CB2 receptor is required for the therapeutic effect of ABHD6 inhibition in experimental autoimmune encephalomyelitis.
    Wen J; Ribeiro R; Tanaka M; Zhang Y
    Neuropharmacology; 2015 Dec; 99():196-209. PubMed ID: 26189763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-Acylethanolamine acid amidase (NAAA) exacerbates psoriasis inflammation by enhancing dendritic cell (DCs) maturation.
    Li Y; Li Y; Xu S; Chen Y; Zhou P; Hu T; Li H; Liu Y; Xu Y; Ren J; Qiu Y; Lu C
    Pharmacol Res; 2022 Nov; 185():106491. PubMed ID: 36244543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation.
    Solorzano C; Zhu C; Battista N; Astarita G; Lodola A; Rivara S; Mor M; Russo R; Maccarrone M; Antonietti F; Duranti A; Tontini A; Cuzzocrea S; Tarzia G; Piomelli D
    Proc Natl Acad Sci U S A; 2009 Dec; 106(49):20966-71. PubMed ID: 19926854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models.
    Sasso O; Moreno-Sanz G; Martucci C; Realini N; Dionisi M; Mengatto L; Duranti A; Tarozzo G; Tarzia G; Mor M; Bertorelli R; Reggiani A; Piomelli D
    Pain; 2013 Mar; 154(3):350-360. PubMed ID: 23218523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses.
    Lee CH; Jeon SJ; Cho KS; Moon E; Sapkota A; Jun HS; Ryu JH; Choi JW
    Mol Neurobiol; 2018 Apr; 55(4):3007-3020. PubMed ID: 28456941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.